GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

GE

314.05

+0.39%↑

RTX

177.49

-1.35%↓

GEV.US

577.41

+0.32%↑

HON

214.26

-0.42%↓

UNP

218.02

-0.56%↓

Search

Ocugen Inc

Открыт

1.52 -1.3

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

1.49

Макс.

1.54

Ключевые показатели

By Trading Economics

Доход

611K

-15M

Продажи

-108K

1.4M

Рентабельность продаж

-1,073.489

Сотрудники

95

EBITDA

724K

-13M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+459.21% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

5 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

188M

506M

Предыдущая цена открытия

2.82

Предыдущая цена закрытия

1.52

Техническая оценка

By Trading Central

Уверенность

Strong Bearish Evidence

Ocugen Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

28 окт. 2025 г., 23:50 UTC

Популярные акции

Stocks to Watch: Caesars, Enphase, Mondelez, Teradyne

28 окт. 2025 г., 23:25 UTC

Отчет

SK Hynix Posts Record Earnings on Continued AI-Chip Demand

28 окт. 2025 г., 23:18 UTC

Отчет

Booking 3Q Sales Rise as U.S. Travel Demand Stabilizes -- Update

28 окт. 2025 г., 22:20 UTC

Отчет

Visa Sales Jump as Consumers Keep Spending -- 2nd Update

28 окт. 2025 г., 22:13 UTC

Отчет

Wal-Mart de Mexico Net Profit Falls in 3Q

28 окт. 2025 г., 21:38 UTC

Отчет

Correction to Visa Sales Jump Article

28 окт. 2025 г., 21:17 UTC

Отчет

OrthoPediatrics Wins FDA Approval for Surgery Plating System; 3Q Revenue Rises

28 окт. 2025 г., 21:07 UTC

Отчет

Visa Sales Jump as Consumers Keep Spending -- Update

28 окт. 2025 г., 21:02 UTC

Отчет

Mondelez Tempers Outlook as Costs Rise

28 окт. 2025 г., 23:51 UTC

Обсуждения рынка

Nikkei May Rise on Easing U.S.-China Tensions -- Market Talk

28 окт. 2025 г., 23:42 UTC

Обсуждения рынка

Gold Edges Lower on Possible Position Adjustments Ahead of FOMC Decision -- Market Talk

28 окт. 2025 г., 23:02 UTC

Отчет

SK Hynix: HBM4 Shipments to Start in 4Q, Ahead of Full-Scale Sales Expansion in 2026

28 окт. 2025 г., 23:01 UTC

Отчет

SK Hynix: Completed Discussions With Key Customers About 2026 HMB Supply

28 окт. 2025 г., 22:46 UTC

Отчет

SK Hynix: Co. Secured Full Customer Demand for Its Entire DRAM and NAND Production for Next Yr >000660.SE

28 окт. 2025 г., 22:45 UTC

Отчет

SK Hynix 3Q Net KRW12.6T >000660.SE

28 окт. 2025 г., 22:44 UTC

Отчет

SK Hynix 3Q Rev KRW24.44T >000660.SE

28 окт. 2025 г., 22:43 UTC

Отчет

SK Hynix 3Q Net Profit Beat FactSet-Compiled Consensus

28 окт. 2025 г., 22:42 UTC

Отчет

SK Hynix 3Q Net KRW12.598T Vs. Net KRW5.753T >000660.SE

28 окт. 2025 г., 22:40 UTC

Отчет

SK Hynix 3Q Rev KRW24.449T Vs. KRW17.573T >000660.SE

28 окт. 2025 г., 22:40 UTC

Отчет

SK Hynix 3Q Oper Pft KRW11.383T Vs. Pft KRW7.030T >000660.SE

28 окт. 2025 г., 22:22 UTC

Отчет

Pharmaron Beijing: Higher Contributions From Clinical-Development Services Supported Results >300759.SZ

28 окт. 2025 г., 22:22 UTC

Отчет

Pharmaron Beijing: Higher Contributions From Laboratory Services Supported Results >300759.SZ

28 окт. 2025 г., 22:22 UTC

Отчет

Pharmaron Beijing 3Q Net CNY439.52M, Up 42.5% on Year >300759.SZ

28 окт. 2025 г., 22:20 UTC

Отчет

Pharmaron Beijing 3Q Rev CNY3.64B, Up 13.4% on Year >300759.SZ

28 окт. 2025 г., 22:02 UTC

Отчет

Review & Preview: Earnings Extravaganza -- Barrons.com

28 окт. 2025 г., 21:42 UTC

Обсуждения рынка
Отчет

Global Equities Roundup: Market Talk

28 окт. 2025 г., 21:42 UTC

Обсуждения рынка
Отчет

Mondelez Says Cocoa Costs Peaked Heading Into Spooky Season -- Market Talk

28 окт. 2025 г., 21:20 UTC

Отчет

Wal-Mart de Mexico 3Q EBITDA MXN25.27B, Up 3.3% on Year

28 окт. 2025 г., 21:19 UTC

Отчет

Wal-Mart de Mexico 3Q Rev MXN241.52B, Up 4.9% on Year

28 окт. 2025 г., 21:18 UTC

Отчет

Wal-Mart de Mexico 3Q Net MXN11.75B, Down 9.2% on Year

Сравнение c конкурентами

Изменение цены

Ocugen Inc Прогноз

Целевая цена

By TipRanks

459.21% рост

Прогноз на 12 месяцев

Средняя 8.5 USD  459.21%

Максимум 15 USD

Минимум 4 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Ocugen Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

4 ratings

4

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

0.6818 / 0.74Поддержка и Сопротивление

Краткосрочная

Strong Bearish Evidence

Среднесрочная

Strong Bullish Evidence

Долгосрочная

No Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
help-icon Live chat